Get the Stockscreener App
269.48
0.78%
2.43
Overview
News
Price History
Option Chain
Financials
Why RMD Down?
Discussions
Forecast
Stock Split
Dividend History
Resmed Inc stock is traded at $269.48, with a volume of 608.68K.
It is up +0.78% in the last 24 hours and up +8.00% over the past month.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
See More
Previous Close:
$267.05
Open:
$267.05
24h Volume:
608.68K
Relative Volume:
0.58
Market Cap:
$39.27B
Revenue:
$5.40B
Net Income/Loss:
$1.49B
P/E Ratio:
26.64
EPS:
10.1168
Net Cash Flow:
$1.78B
1W Performance:
+4.19%
1M Performance:
+8.00%
6M Performance:
-4.04%
1Y Performance:
+13.47%
1-Day Range:
$267.03
$272.33
1-Week Range:
$250.54
$272.33
52-Week Range:
$199.92
$293.81
Resmed Inc Stock (RMD) Company Profile
Name
Resmed Inc
Sector
Industry
Phone
(858) 746-2400
Address
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD vs ISRG, BDX, MDLN, ALC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
269.54 | 38.90B | 5.40B | 1.49B | 1.78B | 10.12 |
|
ISRG
Intuitive Surgical Inc
|
487.85 | 169.16B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
204.92 | 58.84B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
MDLN
Medline Inc
|
47.24 | 38.45B | 27.43B | 1.27B | 1.01B | 1.5829 |
|
ALC
Alcon Inc
|
78.07 | 38.50B | 10.19B | 1.05B | 1.38B | 2.1044 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-18-25 | Initiated | Citigroup | Buy |
| Sep-02-25 | Upgrade | CLSA | Hold → Outperform |
| Jul-15-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-19-25 | Initiated | Morgan Stanley | Overweight |
| Jan-16-25 | Initiated | Goldman | Buy |
| Jan-10-25 | Initiated | Piper Sandler | Neutral |
| Dec-13-24 | Initiated | Stifel | Hold |
| Sep-24-24 | Initiated | Robert W. Baird | Outperform |
| Sep-18-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-04-24 | Downgrade | Needham | Buy → Hold |
| Jun-25-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-24-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Oct-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-12-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-09-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-29-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-06-23 | Upgrade | Needham | Hold → Buy |
| Sep-05-23 | Downgrade | UBS | Buy → Neutral |
| Aug-01-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-23-23 | Initiated | UBS | Buy |
| Apr-14-23 | Initiated | Mizuho | Buy |
| Jan-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-28-22 | Downgrade | Citigroup | Buy → Neutral |
| Oct-20-22 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Sep-08-22 | Upgrade | Citigroup | Neutral → Buy |
| Aug-15-22 | Downgrade | CLSA | Buy → Outperform |
| Aug-12-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-12-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-06-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-31-22 | Upgrade | Citigroup | Neutral → Buy |
| Jan-31-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-28-22 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Jan-24-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-24-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-13-22 | Upgrade | CLSA | Outperform → Buy |
| Jan-13-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-21-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Dec-06-21 | Upgrade | Macquarie | Neutral → Outperform |
| Oct-22-21 | Upgrade | CLSA | Underperform → Outperform |
| Aug-02-21 | Downgrade | CLSA | Outperform → Sell |
| Aug-02-21 | Downgrade | Needham | Buy → Hold |
| Jul-28-21 | Upgrade | Jefferies | Underperform → Hold |
| Jul-26-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-14-21 | Initiated | RBC Capital Mkts | Underperform |
| Jun-28-21 | Downgrade | Citigroup | Buy → Neutral |
| Jun-22-21 | Upgrade | Macquarie | Neutral → Outperform |
| Jun-22-21 | Initiated | Robert W. Baird | Neutral |
| Jun-21-21 | Reiterated | Needham | Buy |
| Jun-16-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-09-21 | Upgrade | CLSA | Sell → Outperform |
| May-21-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-30-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-21 | Upgrade | Needham | Hold → Buy |
| Nov-02-20 | Upgrade | UBS | Neutral → Buy |
| Oct-30-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-27-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-07-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-17-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-01-20 | Downgrade | JP Morgan | Neutral → Underweight |
| May-01-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-18-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-03-20 | Initiated | CLSA | Underperform |
| Jan-31-20 | Downgrade | UBS | Buy → Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Perform |
| Nov-22-19 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jul-29-19 | Upgrade | UBS | Neutral → Buy |
| Jul-16-19 | Downgrade | UBS | Buy → Neutral |
| May-06-19 | Upgrade | UBS | Neutral → Buy |
| Apr-18-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-25-19 | Downgrade | Goldman | Buy → Neutral |
| Jan-25-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-26-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jul-02-18 | Initiated | Goldman | Buy |
View All
Resmed Inc Stock (RMD) Latest News
Resmed: global general counsel Rider sells $13,000 in stock - Investing.com
Resmed director Farrell sells $502k in stock By Investing.com - Investing.com India
ResMed (NYSE:RMD) General Counsel Sells $13,000.00 in Stock - MarketBeat
ResMed (NYSE:RMD) Director Sells $502,620.00 in Stock - MarketBeat
Smart Sand, Inc. Achieves 140.93% Return, Outperforming NetApp and ResMed - Markets Mojo
RMD Stock Up Following Q2 Earnings & Revenue Beat, Margins Expand - tradingview.com
ResMed Chief Legal Officer Sells 50 Common Shares Of Firm - marketscreener.com
ResMed Director Sells 2,000 Shares - marketscreener.com
Why Brambles, HMC Capital, ResMed, and Rio Tinto shares are rising today - The Motley Fool Australia
ResMed Inc (RMD) Stock Price Down 0% on Feb 5 - GuruFocus
The Top 5 Analyst Questions From ResMed’s Q4 Earnings Call - The Globe and Mail
The Top 5 Analyst Questions From ResMed's Q4 Earnings Call - Finviz
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) Gets a Buy from UBS - The Globe and Mail
ResMed Deepens CPAP Lead As Wearables And Digital Tools Expand Reach - Yahoo Finance
ResMed Adjusts CDI and Share Balances Amid Ongoing Capital Management - TipRanks
What can investors expect from ResMed, Cochlear and CSL shares this reporting season? - The Motley Fool Australia
Allianz Asset Management GmbH Acquires 110,647 Shares of ResMed Inc. $RMD - MarketBeat
WCM Investment Management LLC Makes New Investment in ResMed Inc. $RMD - MarketBeat
ResMed Slipped 1% on Profit Beat: Is $400 the 2026 Recovery Target? - TIKR.com
The Truth About ResMed Inc.: Why Everyone Is Suddenly Paying Attention - AD HOC NEWS
Insider Sell Alert: Brett Sandercock Sells Shares of ResMed Inc (RMD) - GuruFocus
ResMed CFO Sells 1,000 Shares Under Pre-Set Trading Plan - TipRanks
ChartWatch ASX Scans: Appen, Aussie Broadband, Flight Centre Travel, Resmed, Siteminder, Sunrise Energy Metals - Market Index
Resmed Founder Receives 2026 Horatio Alger Award - respiratory-therapy.com
Zacks Industry Outlook Highlights Boston Scientific, ResMed, Phibro Animal Health and BioLife Solutions - Yahoo Finance
Sleep device maker ResMed ramps up doctor outreach to tap Ozempic surge - Yahoo Finance
ResMed Inc. (RMD): A Bull Case Theory - Finviz
Ord Minnett Sticks to Its Buy Rating for Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) - The Globe and Mail
ResMed Inc. (RMD) Stock Analysis: A Strong Performer With 15% Upside Potential - DirectorsTalk Interviews
ResMed (RMD) Rating Maintained by Citigroup as Price Target Rises | RMD Stock News - GuruFocus
ResMed Bull Anticipates Further Buybacks -- Market Talk - 富途牛牛
National Pension Service Grows Stake in ResMed Inc. $RMD - MarketBeat
ResMed Inc. $RMD Shares Bought by Mediolanum International Funds Ltd - MarketBeat
Morgans Financial Upgrades ResMed to Buy from Accumulate, Price Target is AU$47.73 - marketscreener.com
Portfolio Shifts: How volatile is ResMed Inc stock2025 Top Gainers & Expert-Curated Trade Recommendations - baoquankhu1.vn
ResMed outlines 62%–63% gross margin target for fiscal 2026 amid double-digit growth in key segments - MSN
ResMed Inc Earnings Call Shows Profitable Growth Momentum - TipRanks
ResMed Bull Stays Positive Amid Strong Revenue Growth -- Market Talk - 富途牛牛
ResMed: Interim result 2026 - intelligentinvestor.com.au
ResMed Files Quarterly Form 10-Q for December 2025 - TipRanks
ResMed Inc. $RMD Shares Acquired by Keybank National Association OH - MarketBeat
ResMed: Facing A Potentially Dream-Disrupting DoseStrong Sell - Seeking Alpha
ResMed (RMD) Net Margin Strength In Q2 2026 Supports Bullish Earnings Narrative - Sahm
Analysts Offer Insights on Healthcare Companies: Stryker (SYK), NewAmsterdam Pharma Company (NAMS) and Resmed (RMD) - The Globe and Mail
ResMed Reaffirms 2025 Risk Profile: No Material Changes to Previously Disclosed Threats - TipRanks
Is Federal Agricultural Mortgage Corporation stock trending bullishGap Down & Technical Pattern Based Buy Signals - baoquankhu1.vn
RMD Q4 Deep Dive: Mask Innovation and Digital Health Expansion Drive Growth - Finviz
KeyBanc raises ResMed stock price target to $302 on solid revenue beat - Investing.com UK
Breaking Down ResMed: 7 Analysts Share Their Views - Benzinga
ResMed’s Profitability Surge Driven by Operational Excellence - AD HOC NEWS
Explore ResMed Market Coverage and Healthcare Sector Context - Kalkine Media
Resmed Inc Stock (RMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.44%
0.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):